PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy
Discover Oncology · 17.06.2024 · 15 (1)
DOI: 10.1007/s12672-024-01091-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 17.06.2024. Verfasst von Jiuru Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Jingkou District, No. 438 Jie Fang Road, Zhenjiang, 212000, Jiangsu, P…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the key research and development plan of Zhenjiang city.
Abstract (Originalsprache)
Objective
To investigate the potential of group I pepsinogen (PG I) and group II pepsinogen (PG II) as diagnostic markers for recurrence in gastric cancer (GC) patients post-total gastrectomy.
Methods
Ninety-six patients who underwent total gastrectomy for GC between June 2022 and June 2023 were included in this study. Clinical data, serum samples, and ascites samples were collected. Patients were categorized based on recurrence status at the time of sample collection and the primary tumor site. PG I and PG II levels were determined using a chemiluminescent immunoassay, and their clinical utility following total gastrectomy for GC was evaluated via receiver operating characteristic (ROC) curve analysis.
Results
This study included 96 GC patients who underwent total gastrectomy, 55 of whom experienced postoperative recurrence (57.29%). The levels of serum PG I (27.86 (27.04, 30.97) vs. 26.05 (24.16, 27.09) ng/mL; P < 0.0001) and PG II (1.95 (1.23, 3.05) vs. 0.63 (0.47, 0.90) ng/mL; P < 0.0001) were significantly greater in the recurrent group compared to the non-recurrent group. The secretion of PG I and/or PG II by metastatic cancer cells correlated with the primary lesion site. When the cut-off value for serum PG I was 26.93 ng/mL, the area under the curve (AUC) for PG I was 0.77. When the cut-off value for serum PG II was 0.96 ng/mL, the AUC reached 0.90. The combined AUC was 0.97.
Conclusion
These findings suggest that serum PG I and PG II are valuable biomarkers for identifying GC patients with biochemical recurrence post-total gastrectomy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Jingkou District, No. 438 Jie Fang Road, Zhenjiang, 212000, Jiangsu, People's Republic of China.
- Department of Ultrasound Medicine, The Affiliated Hospital of Jiangsu University, Jingkou District, No. 438 Jie Fang Road, Zhenjiang, 212000, Jiangsu, People's Republic of China. 1000012984@ujs.edu.cn.
- Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Jingkou District, No. 438 Jie Fang Road, Zhenjiang, 212000, Jiangsu, People's Republic of China. jq1001@ujs.edu.cn.
Förderung
- National Natural Science Foundation of China
- the key research and development plan of Zhenjiang city
Zitieren
APA
Zhang, J., Liu, J., Dong, L., Wang, X., Mao, X., Mao, Y., & Mao, C. (2024). PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01091-0
Vancouver
Zhang J, Liu J, Dong L, Wang X, Mao X, Mao Y, et al. PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01091-0
BibTeX
@article{Zhang2024,
author = {Zhang, Jiuru and Liu, Jiameng and Dong, Liyang and Wang, Xi and Mao, Xueqian and Mao, Yufei and Mao, Chaoming},
title = {PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-01091-0}
}
EUVIMED